This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
|Zacks Rank||Definition||Annualized Return|
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
Cepheid, Inc. (CPHD)
by Zacks Equity ResearchApril 11, 2012 | Comments : 0 Recommended this article: (0)
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at email@example.com or call 800-767-3771 ext. 9339.
While MRSA surveillance continues to be the largest test, its C. difficile test is gaining increasing acceptance. Placements for the HBDC program were encouraging, although Cepheid prefers to hold a cautious stand given funding uncertainties.
Based on an expanding test menu coupled with rising HAI costs, we expect GeneXpert placements to maintain an uptrend. With encouraging guidance for 2012, which exceeded our expectations, we upgrade the stock to Outperform.
Please login to Zacks.com or register to post a comment.